Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus recommendation of "Buy" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $54.33.

DNTH has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DNTH. Bank of New York Mellon Corp increased its stake in shares of Dianthus Therapeutics by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock valued at $1,336,000 after purchasing an additional 748 shares in the last quarter. Moody Aldrich Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $1,349,000. GAMMA Investing LLC increased its position in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares in the last quarter. Wellington Management Group LLP raised its stake in Dianthus Therapeutics by 12.2% during the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after buying an additional 6,552 shares during the last quarter. Finally, Woodline Partners LP raised its stake in Dianthus Therapeutics by 20.0% during the fourth quarter. Woodline Partners LP now owns 300,504 shares of the company's stock valued at $6,551,000 after buying an additional 50,000 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Trading Down 7.2 %

Shares of NASDAQ:DNTH traded down $1.56 on Thursday, reaching $19.99. 312,497 shares of the company traded hands, compared to its average volume of 264,964. The stock has a market capitalization of $642.20 million, a P/E ratio of -8.00 and a beta of 1.48. The business's 50-day simple moving average is $19.85 and its 200 day simple moving average is $22.57. Dianthus Therapeutics has a 52 week low of $13.37 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.